IRA’s Orphan Drug Exemption Could Lead to More Off-Label Prescribing

Rare disease advocates also argue that the Medicare’s government drug price negotiation orphan drug exemption – which only applies when a drug has one orphan designation – will harm other government efforts aimed at more efficient drug development.